The DOI matches its Crossref record.
Antitumor activity of recombinant interleukin 6 in mice.
Open accessAbstract
IL-6 possesses multiple biologic activities that affect a broad range of cells including those directly involved in immune responses as well as cells important in the systemic response to infection or trauma. We now show that purified human rIL-6, when administered alone at relatively high doses that are comparable to therapeutic levels of IL-2, mediated substantial reductions in the number of pulmonary and hepatic micrometastases from four distinct syngeneic tumors. Unlike IL-2, IL-6 injections resulted in neither observable toxicity nor death of the treated mice at the dose regimens used. Host immunosuppression by sublethal total-body irradiation before the initiation of therapy prevented the IL-6 antitumor effect, thus suggesting that IL-6 acted through a radiosensitive host component rather than directly on the tumor itself. Moreover, the systemic administration of relatively low doses of IL-6 in combination with subtherapeutic doses of TNF to mice bearing an established weakly immunogenic, syngeneic tumor at a subcutaneous site resulted in marked tumor regression and cure rates. These studies represent the first demonstration of tumor regression mediated by recombinant IL-6 in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Interleukin‐6: A Cytokine for Gerontolgists
Ershler, W. B. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02054.x · Cited by 469
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationCytokine activation of the HPA axis
DUNN, A. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05426.x · Cited by 352
Control of programmed cell death in normal and leukemic cells: new implications for therapy
Sachs, L., & Lotem, J. (1993) · Blood · doi:10.1182/blood.v82.1.15.bloodjournal82115 · Cited by 284
Asher, A. L., Mulé, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., & Rosenberg, S. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3227 · Cited by 281
Self-citationInterleukin-6 and Cardiovascular Diseases
Kanda, T., & Takahashi, T. (2004) · Japanese Heart Journal · doi:10.1536/jhj.45.183 · Cited by 265
de la Mata, J., Uy, H. L., Guise, T. A., Story, B., Boyce, B. F., Mundy, G. R., & Roodman, G. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117990 · Cited by 255
Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells
Tepper, R. I., & Mulé, J. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-153 · Cited by 254
Self-citationDifferences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients
Nieken, J., Mulder, N., Buter, J., Vellenga, E., Limburg, P., Piers, D., & de Vries, E. (1995) · Blood · doi:10.1182/blood.v86.3.900.900 · Cited by 128
Visseren, F. L. J., Verkerk, M. S. A., Van Der Bruggen, T., Marx, J. J. M., Van Asbeck, B. S., & Diepersloot, R. J. A. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1084.x · Cited by 64
Metadata
- Authors
- Mulé, J. J., McIntosh, J. K., Jablons, D. M., & Rosenberg, S. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1990-03-01
- Volume
- 171
- Issue
- 3
- Pages
- 629-636
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2006704738
- Cited by
- 227
- References
- 0
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.